Fundraising Fox
David V. Goeddel, PhD
InvestorPartner Emeritus at The Column Group
Find your path to David
49 people in our graph can introduce you to David.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Tim Kutzkey to introduce you to David
You →Tim · together at The Column Group →David
Ask Jamie Chen to introduce you to David
You →Jamie · 11 people · together at The Column Group →David
Sign up to find every way you can get introduced to David
- Your email: the people you already email who know David
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with David
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
About
David V. Goeddel led creation of the first marketed recombinant therapeutics (including insulin and growth hormone), and built Tularik to IPO and sale to Amgen, with a rare scientist-CEO perspective.
Invests in
BiotechHealthtech
Colleagues at The Column Group
Aadit Shah
Principal at The Column Group
Arnav Mehta, MD, PhD
Venture Partner at The Column Group
Betty Liu
Swanson Fellow at The Column Group
Brooke Sorenson
Administrative Coordinator at The Column Group
Carla Daniel
Partner at The Column Group
Charles Sawyers
Science Partner at The Column Group
Charles Zuker
Science Partner at The Column Group
Craig Parker
Venture Partner at The Column Group
Frequently asked questions
- Who is David V. Goeddel, PhD?
- David V. Goeddel led creation of the first marketed recombinant therapeutics (including insulin and growth hormone), and built Tularik to IPO and sale to Amgen, with a rare scientist-CEO perspective.
- Where does David V. Goeddel, PhD work?
- David V. Goeddel, PhD is Partner Emeritus at The Column Group.
- What does David V. Goeddel, PhD invest in?
- David V. Goeddel, PhD invests in Biotech, Healthtech.